Advanced search
Publication Cover
Scandinavian Journal of Gastroenterology Volume 47, 2012 - Issue 8-9
Submit an article Journal homepage
146
Views
3
CrossRef citations to date
0
Altmetric
Short Report

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C

Peer Brehm ChristensenDepartment of Infectious Diseases, Odense University Hospital, Odense, DenmarkCorrespondence[email protected]
,
Henrik Bygum KrarupDepartment of Medical Gastroenterology and Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
,
Alex Lund LaursenDepartment of Infectious Diseases, Skejby University Hospital, Aarhus, Denmark
,
Poul Henning MadsenDepartment of Medical Gastroenterology and Department of Clinical Biochemistry, Aalborg University Hospital, Aalborg, Denmark
,
Court PedersenDepartment of Infectious Diseases, Odense University Hospital, Odense, Denmark
,
Poul SchlichtingDepartment of Gastroenterology, Herlev Hospital, Copenhagen University, Denmark
,
Marianne OrholmDepartment of Internal Medicine, Elsinore Hospital, Elsinore, Denmark
,
Helmer Ring-LarsenDepartment of Hepatology, H:S Rigshospitalet, and Department of Pharmacology and Pharmacotherapy, Faculty of Pharmaceutical Sciences, University of Copenhagen, Denmark
,
Jens BukhCopenhagen Hepatitis C Program (CO-HEP), Department of Infectious Diseases and Clinical Research Centre, Copenhagen University Hospital, Hvidovre and Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, Denmark
&
Kim KrogsgaardClinical Research Centre, Copenhagen University Hospital, Hvidovre, Denmark
 show all
Pages 1115-1119 | Received 12 May 2012, Accepted 15 May 2012, Published online: 07 Jun 2012

References

  • Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195–206.
  • Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405–16.
  • Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399–401.
  • Poordad F, Reddy KR, Martin P. Rapid virologic response: a new milestone in the management of chronic hepatitis C. Clin Infect Dis 2008;46:78–84.
  • Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FLJ, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975–82.
  • Krarup HB, Drewes AM, Madsen PH. A quantitative HCV-PCR test for routine diagnostics. Scand J Clin Lab Invest 1998;58:415–22.
  • Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C, Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798–801.
  • Hansen N, Obel N, Christensen PB, Kjaer M, Laursen AL, Krarup HB, Effectiveness of treatment with pegylated interferon and ribavirin in an unselected population of patients with chronic hepatitis C: a Danish nationwide cohort study. BMC Infect Dis 2011;11:177.
  • Hadziyannis SJ, Sette HJ, Morgan TR, Balan V, Diago M, Marcellin P, Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346–55.
  • Dienstag JL, McHutchison JG. American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006;130:231–64.
  • Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology 2008;47:1837–45.
  • Feld J, Lucthman G, Loomba R, Modi A, Rotman Y, Nagabhyru P, Twice vs once weekly dosing of peginterferon alfa 2a in chronic HCV genotype 1 infection: analysis of early viral kinetics. Hepatology 2007;46:343A.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.